Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Liabilities (2021 - 2026)

Zentalis Pharmaceuticals has reported Total Liabilities over the past 6 years, most recently at $70.4 million for Q1 2026.

  • For Q1 2026, Total Liabilities fell 20.59% year-over-year to $70.4 million; the TTM value through Mar 2026 reached $70.4 million, down 20.59%, while the annual FY2025 figure was $72.8 million, 21.89% down from the prior year.
  • Total Liabilities for Q1 2026 was $70.4 million at Zentalis Pharmaceuticals, down from $72.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $114.3 million in Q4 2023 and troughed at $70.4 million in Q1 2026.
  • A 5-year average of $93.6 million and a median of $96.3 million in 2024 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: grew 16.95% in 2022 and later decreased 29.23% in 2025.
  • Year by year, Total Liabilities stood at $105.3 million in 2022, then increased by 8.56% to $114.3 million in 2023, then decreased by 18.5% to $93.2 million in 2024, then dropped by 21.89% to $72.8 million in 2025, then dropped by 3.27% to $70.4 million in 2026.
  • Business Quant data shows Total Liabilities for ZNTL at $70.4 million in Q1 2026, $72.8 million in Q4 2025, and $74.4 million in Q3 2025.